This is Why Pfizer’s Quarterly Revenue Missed Wall Street Expectations
Before the market opened on Tuesday, Pfizer Inc. (NYSE:$PFE) reported its quarterly revenue. Unfortunately, the revenue missed Wall Street estimates. Many speculate the miss in quarterly revenue was caused by a lower demand for Enbrel …
Merck & Company Reported a Quarter Two Earnings Increase
On Friday, July 28, Merck & Company (NYSE:$MRK) announced that its Q2 earnings increased as the drugmaker had blockbuster growth for its cancer drug Keytruda.
Based on the Q2 earnings report, Merck’s new …
Bristol-Myers Reported Q2 Profit Match and Revenue Beat, But Shares Still Fell 6.2%
On July 27, Bristol-Myers Squibb Co. (NYSE:$BMY) reported a Q2 profit match and revenue beat. However, shares fell 6.2% in pre-market trade after AstraZeneca’s late-stage clinical trial failed. Why did this affect the company’s stock? …
Tetraphase Pharmaceuticals Saw an Increase in Shares Today, Here’s Why!
Tetraphase Pharmaceuticals (NASDAQ:$TTPH) saw an increase in shares today. And when I say increase, I mean a whopping 27% increase. It all started after the Watertown, Massachusetts-based company disclosed positive top-line results for a phase …
Eli Lilly Releases Q2 Earnings Report, Beats Profit and Sales Expectations
On July 25, Eli Lilly & Company (NYSE:$LLY) reported a Q2 net profit that increased to $1.01 billion (95 cents a share) from $747.7 million (71 cents a share), in the same time frame in …
The Latest Creation From the Cannabis Sector is a Cannabis-Infused Keurig Cup Line
Now that support for cannabis has grown to a majority, the question of national legalization is not so much a matter of “if” but “when.”
Until this point, the cannabis sector in California …
Teva Pharmaceuticals Sees Small Rise in Stock After Announcing New CEO
Pascal Sorio will be leaving pharmaceutical company AstraZeneca (LON:$AZN) as CEO to assume the CEO position at Teva Pharmaceuticals (NYSE:$TEVA) instead, according to Israeli business website Calcalist.
Sorio agreed to assume the role …
Mylan Faces More Criticism for Excessive Pay Package to Its Top Executives
Although it had just recently faced a great scandal for continuously raising the prices of EpiPens and have been performing quite poorly on the stock market, pharmaceutical company Mylan (NASDAQ:$MYL) just paid its chairman and …
Johnson & Johnson Finally Receives Data from SGLT-2 Inhibitor, Invokana
Hold onto your hats, pharmaceutical investors! Johnson & Johnson (), an American multinational pharmaceutical company, has finally received it’s data from Invokana, which is a popular SGLT-2 inhibitor used to treat type 2 diabetes.
… Read
Adamis Pharmaceuticals’ Shares Hits New Highs After Allergic-Reaction Treatment Drug Gains FDA Approval
Investors in Adamis Pharmaceuticals Corp. (NASDAQ:$ADMP) were probably celebrating yesterday as the company’s shares flew through the roof by a whopping 53%, hitting a one-year high. The rise was largely due to Adamis’ announcement that …